FDA tells Pfizer to hold it
Executive Summary
Pfizer receives an "approvable" letter from FDA for the overactive bladder treatment fesoterodine, which it acquired from Schwarz in April. Pfizer's market-leading urinary incontinence therapy Detrol LA (tolterodine) has been competing in an increasingly crowded market, and faces patent expiry in 2012 (1"The Pink Sheet" Aug. 15, 2005, p. 5)...